Data presented by Dr. Francisco Sánchez León in London show reliably good uncorrected vision at distance, intermediate and near, in daylight and in low light, with no serious adverse events and every patient free of halos Results Z Optics IOL Summary of Dr. Sanchez' results with the results Z Optics IOL, as presented during the ESCRS congress in London, 2026. RENO, Nev., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Z Optics Inc., a medical device company developing the Z+ Virtual Aperture intraocular l

Poster presentations further characterize clinical pro HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters eval

Collaboration integrates cognitive assessment, proprietary blood test, national phlebotomy and MRI infrastructure to accelerate patient diagnosis and care pathways throughout the UK LONDON--(BUSINESS WIRE)-- #Alzheimers -- C2N Diagnostics, LLC ("C2N"), a pioneer in advanced diagnostic testing for brain health, and Cambridge Cognition , the neuroscience technology company, announce on World Alzheimer’s Day a partnership with The Alzheimer's Trust, a newly formed subsidiary of The Cancer Screen

In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have achieved MRD-negative complete responses following a single administration of VNX-101 Responses have demonstrated encouraging durability for all three patients, with the first patient remaining MRD-negative through Day 260 VNX-101 is a novel, one-time, off-the-shelf immunotherapy that enables the body to produce a CD19/CD3 T-cell–engaging protein, demonstr

New high-field NMR instrumentation strengthens biomolecular and materials science research at the UC Berkeley Pines Magnetic Resonance Center BERKELEY, Calif.--(BUSINESS WIRE)-- $BRKR #BRKR -- Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800

Following a horizontal acquisition in December 2025, the companies are realising marked synergies under an ambitious integration program that has successfully aligned manufacturing processes to enable a full dual source supply strategy, which is being launched at CPHI Milan, 6–8 October 2026. Working to an ambitious timeline for full post-merger integration, Gaelic Laboratories and Athlone Laboratories are attaining marked synergies under a strong leadership team that is driving process and cost

The biosimilar candidate is intended to reference Hemlibra (emicizumab), which addresses haemophilia A, a genetic disorder. Credit: angellodeco/Shutterstock.com. Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia A. The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the ref

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis --Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate acc

Novartis’ Cosentyx (secukinumab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation in polymyalgia rheumatica (PMR). The opinion supports Cosentyx use for treatment of PMR in adults who have had an inadequate response to steroids or who experience relapse during steroid taper. If approved, Cosentyx would be the first interleukin-17A (IL-17A) inhibitor approved in Europe for peo

New Phase 3 analyses of Olanzapine LAI, currently under regulatory review, provided further insights into stabilization, long-term efficacy and treatment-switching strategies Additional real-world data reinforced UZEDY's clinical and economic benefits in the management of schizophrenia and bipolar I disorder care MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY ® , two treatments utilizing Medin